A therapeutic agent and a treatment method for uremia of human and animals,which therapeutic agent can be easily taken, has lower side effects, and whichis notexpensive in view of medical economics, are disclosed. The therapeutic agentforuremia in patients suffering from chronic renal failure comprises as aneffectiveingredient a prostaglandin I2 derivative having a specific structure, such asberaprostsodium. The therapeutic agent for uremia ameliorates the uremia concurred inpatients with chronic renal failure without accompanying side effects, andrestorationof decreased appetite, improvements in activities, increase in body weight andthelike are achieved. The therapeutic effect of uremia is clear alleviation ordisappearance of symptoms of uremia grasped as clinical symptoms, observed inthestate of renal failure, especially even in spite of the state wherein thedecrease inrenal function is progressed.
